Abstract
With the current rise in multiresistant gram-negative bacteria, carbapenems are more frequently used. Surprisingly, limited data exist on the pharmacokinetics of meropenem in peritoneal dialysis (PD)-related peritonitis. We report on the pharmacokinetics of repeated intraperitoneal (IP) meropenem during 21 days as treatment for polymicrobial multiresistent PD-related peritonitis.Our current report supports daily doses of 125 mg/L intraperitoneal meropenem in all bags as an effective and safe modality in the treatment of PD-associated peritonitis with multiresistant microorganisms. No signs of over- or underdosing were found based on serial drug concentration measurements at fixed time points up to 21 days.
| Original language | English |
|---|---|
| Pages (from-to) | 572-3 |
| Number of pages | 2 |
| Journal | Peritoneal Dialysis International |
| Volume | 36 |
| Issue number | 5 |
| DOIs | |
| Publication status | Published - 24 Sept 2016 |
Keywords
- Aged, 80 and over
- Anti-Bacterial Agents/pharmacokinetics
- Drug Resistance, Multiple
- Female
- Follow-Up Studies
- Humans
- Infusions, Parenteral
- Kidney Failure, Chronic/diagnosis
- Meropenem
- Patient Safety
- Peritoneal Dialysis, Continuous Ambulatory/adverse effects
- Peritonitis/drug therapy
- Thienamycins/pharmacokinetics
- Treatment Outcome
Fingerprint
Dive into the research topics of 'Intraperitoneal Meropenem for Polymicrobial Peritoneal Dialysis-Related Peritonitis'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver